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Background
A new class of autoinflammatory syndromes called
NLRP12-associated disorders (NLRP12AD) has been
associated with mutations in NLRP12. Conflicting data
on the putative role of NLRP12 in IL-1b signaling have
been generated in vitro.
Aim
This prospective study was undertaken to assess the
secretion of IL-1b and three IL-1b-induced cytokines
(IL-1Ra, IL-6 and TNF-a) in patients’ PBMC cultured ex
vivo and to evaluate the patients’ response to recombi-
nant IL-1 receptor antagonist (IL-1Ra, anakinra), a
major drug in the treatment of autoinflammatory
disorders.
Methods
Patients’ disease manifestations and cytokine measure-
ments were recorded before anakinra treatment was
started, during 14 months of therapy, and after disconti-
nuation of anakinra treatment.
Results
Spontaneous secretion of IL-1b by patients’ PBMC was
found to be dramatically increased (80 to 175-fold) com-
pared to controls. Consistently, anakinra initially led to a
marked clinical improvement and to a rapid near-nor-
malization of IL-1b secretion. However, a progressive
clinical relapse occurred secondarily, associated with an
increase in TNF-a secretion, persistent elevated levels of
IL-1Ra and IL-6 and a reactivation of IL-1b secretion.
Anakinra was discontinued after 14 months of therapy.
Conclusion
Our findings provide in vivo evidence of the crucial role
of IL-1b in the pathophysiology of NLRP12AD. This is
the first time anakinra has been used to treat this disor-
der. This study provides new insights into the mechan-
isms underlying resistance to anti–IL-1 therapy
observed in few patients with autoinflammatory syn-
dromes. Our data also point to the potential interest of
cytokine ex vivo measurements as predictors of response
to treatment.
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